NASDAQ:GRPH

Graphite Bio (GRPH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$3.05
$3.23
50-Day Range
$3.18
$26.11
52-Week Range
$2.01
$4.26
Volume
328,300 shs
Average Volume
282,405 shs
Market Capitalization
$185.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GRPH stock logo

About Graphite Bio Stock (NASDAQ:GRPH)

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.

GRPH Stock News Headlines

Versant Vantage II, L.P.'s Net Worth
GRPH Mar 2024 5.000 put
VERI, STI and VERB among mid-day movers
GRPH Mar 2024 7.500 call
Graphite Bio, Inc. (GRPH)
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
Graphite Bio To Merge With LENZ Therapeutics; Stock Down In Pre-market
Graphite Bio Inc GRPH
See More Headlines
Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2023
Ex-Dividend for 3/21 Dividend
3/15/2024
Dividend Payable
3/21/2024
Today
5/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GRPH
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
$-124,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.15 per share

Miscellaneous

Free Float
35,874,000
Market Cap
$185.20 million
Optionable
Not Optionable
Beta
0.20
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Matthew Porteus M.D. (Age 58)
    Ph.D., Academic Founder & Director
    Comp: $110k
  • Stephanie Yao
    Vice President of Communications & Investor Relations
  • Dr. Christine Garrett P.M.P. (Age 53)
    Ph.D., Chief Strategy Officer

GRPH Stock Analysis - Frequently Asked Questions

How were Graphite Bio's earnings last quarter?

Graphite Bio, Inc. (NASDAQ:GRPH) released its quarterly earnings data on Monday, March, 20th. The company reported ($3.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.43) by $0.35.

How often does Graphite Bio pay dividends? What is the dividend yield for Graphite Bio?

Graphite Bio declared a dividend on Friday, March 15th. Shareholders of record on Monday, March 18th will be given a dividend of $7.21 per share on Thursday, March 21st. This represents a yield of 28.93%. The ex-dividend date of this dividend is Friday, March 15th.
Read our dividend analysis for GRPH
.

When did Graphite Bio's stock split?

Graphite Bio's stock reverse split on the morning of Friday, March 22nd 2024. The 1-7 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

When did Graphite Bio IPO?

Graphite Bio (GRPH) raised $224 million in an IPO on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share.

This page (NASDAQ:GRPH) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners